Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
REVENUES:
TOTAL REVENUES	$ 6,616,100	$ 0	$ 6,616,100	$ 30,430
Costs of sales	3,912,741	0	3,912,741	0
GROSS PROFIT	2,703,359	0	2,703,359	30,430
OPERATING EXPENSES:
Research and development	1,551,988	1,207,302	3,494,221	3,116,097
Selling, marketing and administrative	11,013,221	1,981,037	19,147,297	6,681,452
TOTAL OPERATING EXPENSES	12,565,209	3,188,339	22,641,518	9,797,549
OPERATING LOSS	(9,861,850)	(3,188,339)	(19,938,159)	(9,767,119)
OTHER INCOME (EXPENSE):
Interest income (expense), net	3,663	(72,705)	(1,843)	(267,213)
Change in fair value of warrant liability	(11,784,305)	134,552	(29,747,367)	2,804,962
TOTAL OTHER INCOME (EXPENSE)	(11,780,642)	61,847	(29,749,210)	2,537,749
LOSS BEFORE INCOME TAXES	(21,642,492)	(3,126,492)	(49,687,369)	(7,229,370)
Income taxes	0	0	0	0
NET LOSS	(21,642,492)	(3,126,492)	(49,687,369)	(7,229,370)
Preferred dividends and beneficial conversion feature	0	(499,797)	(2,524,958)	(1,227,422)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (21,642,492)	$ (3,626,289)	$ (52,212,327)	$ (8,456,792)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.80)	$ (0.40)	$ (2.34)	$ (0.92)
Weighted average shares of common shares - basic and diluted (in shares)	26,911,855	9,156,260	22,342,538	9,156,260
Product [Member]
REVENUES:
TOTAL REVENUES	$ 6,616,100	$ 0	$ 6,616,100	$ 0
Grant [Member]
REVENUES:
TOTAL REVENUES	$ 0	$ 0	$ 0	$ 30,430